Successful outcome of acute Graft-versus-host disease in a liver allograft recipient by withdrawal of immunosuppression

被引:69
作者
Lehner, F
Becker, T
Sybrecht, L
Lück, R
Schwinzer, R
Slateva, K
Blasczyk, R
Hertenstein, B
Klempnauer, J
Nashan, B
机构
[1] Med Hochschule Hannover, Viszeral & Transplantat Chirurg Klin, D-30625 Hannover, Germany
[2] Med Hochschule Hannover, Abt Transfus Med, D-30625 Hannover, Germany
[3] Med Hochschule Hannover, Abt Hamatol & Onkol, D-30625 Hannover, Germany
关键词
D O I
10.1097/00007890-200201270-00030
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Graft-versus-host disease (GVHD) after liver transplantation is uncommon, and the outcome is almost always fatal. Since 1987, about 30 cases have been described, and patient survival is mostly exceptional. Methods. A 29-year-old man underwent retransplantation due to chronic cholestatic syndrome, 5 years after his first liver transplantation. Indication for the first liver transplantation was acute liver failure caused by exsiccosis. After the second transplantation, the patient had an initially uneventful course, developing thrombocytopenia at day 21 followed by skin rash and septic complications. Diagnosis of acute GVHD was made by using serological techniques for HLA-A and HLA-DRB and subsequently by fluorogenic sequence-specific primed polymerase chain reaction. In addition, donor lymphocytes were marked by immunohistochemical methods via biopsies of the skin. Immunosuppressive therapy was withdrawn to allow the patient's own immune system to eliminate donor cells. Results. By withdrawing the immunosuppressive therapy, clinical and morphological signs of GVHD vanished. The patient is doing well without recurrence 13 months after transplantation. Conclusion. Withdrawal of immunosuppressive therapy is a promising approach in the treatment of acute GVHD to allow the patient's immune system to reconstitute itself, reject offending lymphocytes, and avoid lethal septic complications.
引用
收藏
页码:307 / 310
页数:4
相关论文
共 16 条
[1]   Fluorotyping of HLA-DRB by sequence-specific priming and fluorogenic probing [J].
Albis-Camps, M ;
Blasczyk, R .
TISSUE ANTIGENS, 1999, 53 (03) :301-307
[2]  
BADOSA F, 1987, TRANSPLANT P, V19, P3822
[3]   SEVERE GRAFT-VERSUS-HOST DISEASE IN A LIVER-TRANSPLANT RECIPIENT [J].
BURDICK, JF ;
VOGELSANG, GB ;
SMITH, WJ ;
FARMER, ER ;
BIAS, WB ;
KAUFMANN, SH ;
HORN, J ;
COLOMBANI, PM ;
PITT, HA ;
PERLER, BA ;
MERRITT, WT ;
WILLIAMS, GM ;
BOITNOTT, JK ;
HERLONG, HF .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (11) :689-691
[4]   SURVIVAL OF GRAFT-VERSUS-HOST DISEASE IN A LIVER-TRANSPLANT RECIPIENT [J].
CATTRAL, MS ;
LANGNAS, AN ;
WISECARVER, JL ;
HARPER, JC ;
RUBOCKI, RJ ;
BYNON, JS ;
FOX, IJ ;
HEFFRON, TG ;
SHAW, BW .
TRANSPLANTATION, 1994, 57 (08) :1271-1274
[5]   GRAFT-VERSUS-HOST DISEASE IN A LIVER-TRANSPLANT RECIPIENT [J].
COLLINS, RH ;
COOPER, B ;
NIKAEIN, A ;
KLINTMALM, G ;
FAY, JW .
ANNALS OF INTERNAL MEDICINE, 1992, 116 (05) :391-392
[6]  
JAMIESIN NV, 1990, TRANSPLANT P, V22, P2378
[7]   Peripheral blood chimerism following human liver transplantation [J].
Jonsson, JR ;
Hogan, PG ;
Thomas, R ;
Steadman, C ;
Clouston, AD ;
Balderson, GA ;
Lynch, SV ;
Strong, RW ;
Powell, EE .
HEPATOLOGY, 1997, 25 (05) :1233-1236
[8]   Graft versus host disease in a liver transplant patient with hepatitis B and hepatocellular carcinoma [J].
Merhav, HJ ;
Landau, M ;
Gat, A ;
Gazit, E ;
Baratz, M ;
Bialy-Golan, A ;
Konikof, F ;
Bril, S ;
Nakache, R .
TRANSPLANTATION PROCEEDINGS, 1999, 31 (04) :1890-1891
[9]  
ROBERTS JP, 1991, HEPATOLOGY, V14, P274, DOI 10.1016/0270-9139(91)91415-W
[10]  
SanchezIzquierdo JA, 1996, HEPATO-GASTROENTEROL, V43, P1057